International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"Efficacy and safety of thermal ablation for T1N0M0 papillary thyroid cancer in pediatric and adolescent patients - a preliminary multicenter retrospective study.","authors":"Zhenlong Zhao, Shurong Wang, Shengnan Huo, Jinke Li, Lu Zhou, Lihong Liu, Songsong Wu, Zhibin Cong, Ying Wei, Jie Wu, Shiliang Cao, Na Yu, Yan Li, Ming'an Yu","doi":"10.1080/02656736.2025.2539182","DOIUrl":"https://doi.org/10.1080/02656736.2025.2539182","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of thermal ablation (TA) for T1N0M0 PTC in pediatric and adolescent patients who refused surgery.</p><p><strong>Materials and methods: </strong>This was a retrospective multicenter study of 25 pediatric and adolescent patients (19 females) who underwent TA for T1N0M0 between August 2015 and November 2023. The median age of the patients was 18 years (range, 10-18 years), and the median follow-up time was 27 months (range, 12-60 months). Ablation zone disappearance, tumor progression, and complications were assessed.</p><p><strong>Results: </strong>The technical success rate was 100%. The median time for ablation zone absorption was 12 months in the T1a group and 18 months in the T1b group (log-rank <i>p</i> = 0.027). The tumor progression rate was 4.0%, with one case of lymph node metastasis at the 24-month follow up. The 1-, 3- and 5-year progression free survival rates were 100%, 93.8%, and 93.8%, respectively. No major complications were encountered. Mild thyroid function abnormality was observed in two patients at the 1-month follow up, both of whom recovered without treatment.</p><p><strong>Conclusions: </strong>This multicenter study provideds evidence that TA is an effective and safe treatment option in selected pediatric and adolescent patients with T1N0M0 PTC.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2539182"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study.","authors":"Stella Chin-Shaw Tsai, Yi-Min Chen, Yueh-Han Ku, Chia-Hsuan Hsu, Tzu-Hsuan Hsiao, Pin-Hsu Liao, Tzu-Chin Wu, Frank Cheau-Feng Lin","doi":"10.1080/02656736.2024.2449473","DOIUrl":"https://doi.org/10.1080/02656736.2024.2449473","url":null,"abstract":"<p><strong>Background: </strong>Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges, with limited effective therapies for late-stage patients. This study aimed to evaluate the impact of adding thermal ablation (TA) in treatment regimens for advanced NSCLC to improve survival outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at a medical center in Taiwan, analyzing data from 1,083 patients diagnosed with stage IIIB or IV NSCLC between 2008 and 2020. Survival outcomes were compared between patients treated with TA and those who received conventional therapies. Statistical analyses, including propensity score matching and Cox regression models, were used to account for potential confounders.</p><p><strong>Results: </strong>The TA group demonstrated a significantly longer median overall survival (OS) of 37 months compared to 15 months in the non-TA group (<i>p</i> < 0.001), with five-year OS rates of 32.4% and 9.8%, respectively. Median progression-free survival (PFS) was 36 months in the TA group versus 14 months in the non-TA group, with five-year PFS rates of 24.1% versus 6.3% (<i>p</i> < 0.001). Subgroup analyses showed enhanced survival in patients undergoing targeted therapy and chemotherapy when TA was included. Survival outcomes with TA were comparable to lobectomy, offering a less invasive option for selected patients.</p><p><strong>Conclusions: </strong>Thermal ablation is associated with significant improvements in OS and PFS in patients with advanced NSCLC, providing a viable treatment option for those not eligible for surgery. The results support the integration of TA into standard care protocols, with further prospective studies needed to confirm these findings and optimize treatment strategies.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2449473"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platform-based BST-2-targeted microbubbles enhance HIFU therapy and effectively inhibit prostate cancer residual growth.","authors":"Hang Zhou, Jia Tang, Yujie Wan, Jiaqi Gong, Qizhi Wang, Kaifeng Huang, Ruixia Hong, Xinzhi Xu, Fang Li","doi":"10.1080/02656736.2025.2511035","DOIUrl":"10.1080/02656736.2025.2511035","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the potential of BST2-targeted microbubble-facilitated HIFU therapy for prostate cancer (PCa), and to elucidate the mechanisms of synergistic tumor suppression in residual lesions.</p><p><strong>Methods: </strong>The specificity of BST-2 expression in PCa tumor endothelial cells was established using a cellular co-culture method. The targeting efficacy of Anti-BST-2 antibody-conjugated microbubbles (BST-2-MB) was evaluated both <i>in vitro</i> and <i>in vivo</i>. The therapeutic outcomes of BST-2-MB-augmented HIFU (High-Intensity Focused Ultrasound) for PCa in Balb/c mice were compared with those of non-targeted microbubbles and HIFU alone. Changes in the immunological microenvironment and modulation of BST-2-related oncogenic pathways in residual tumors were analyzed using Western Blot, immunofluorescence, flow cytometry, and ELISA.</p><p><strong>Results: </strong>BST-2 is highly expressed in PCa vascular endothelial cells, and BST-2-MBs show strong targeting efficacy. HIFU combined with BST-2-MB achieved larger ablation volumes and potent inhibition of residual tumor growth. This treatment induced more immunogenic cell death (ICD), DC maturation, and CD8+ T cell infiltration, and significantly downregulated the expression of BST-2, EGFR, pSTAT3, and pErk1/2 compared to other treatments.</p><p><strong>Conclusion: </strong>BST-2-MB combined with HIFU therapy demonstrates a superior synergistic antitumor effect in PCa, effectively inhibiting residual tumors, which offers a novel strategy to enhance HIFU efficacy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2511035"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex parity in stimulation of murine lymphocyte trafficking in response to fever-range systemic thermal therapy.","authors":"Michelle M Appenheimer, Arwen A Tisdale, Daniel T Fisher, Han Yu, Elizabeth A Repasky, Sharon S Evans","doi":"10.1080/02656736.2025.2526118","DOIUrl":"https://doi.org/10.1080/02656736.2025.2526118","url":null,"abstract":"<p><p>Murine preclinical studies established that hyperthermia regimens stimulate immunity by mobilizing lymphocyte homing to lymph nodes and tumors. Enhanced lymphocyte trafficking during fever-range systemic thermal therapy (FR-STT) is driven by interleukin-6 (IL-6) upregulation of intercellular adhesion molecule-1 (ICAM-1) on blood vessels in lymph nodes and tumors. However, since hyperthermia regulation of lymphocyte homing was only evaluated in female mice, the response of male mice remains unknown. Here, we investigated the potential sex bias in response to FR-STT by assessing the function of lymph node high endothelial venules (HEV) that are a thermally-responsive vascular site. Although it was feasible to elevate core temperatures to 39.5 ± 0.5 °C for 6 h in female and male mice, males were significantly less tolerant to FR-STT. Under normothermic controls, there was no difference between females and males in baseline intranodal (a) HEV frequency, (b) HEV area, (c) IL-6 concentration, and (d) lymphocyte trafficking. FR-STT further induced similar increases in ICAM-1 expression on HEV and lymphocyte trafficking in lymph nodes in both sexes. While FR-STT did not alter intranodal IL-6 concentrations, findings that IL-6 was higher in lymph nodes than the circulation in both sexes suggest that local IL-6 is responsible for systemic vascular responses to FR-STT. Collectively, these data demonstrate that despite sexual dimorphism in thermal regulation in mice, there was no evidence of a sex bias for lymphocyte homing at checkpoint HEV. Thus, hyperthermia treatment is predicted to be equally effective in boosting immunity in male and female mice when combined with immunotherapy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2526118"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mathematical modeling of the effect of stent construction during endoluminal IRE for recanalization of an occluded metal stent.","authors":"Peter Matkulcik, Martin Hemzal, Tomas Rohan, Dalibor Cervinka, Veronika Novotna, Shraga Nahum Goldberg, Tomas Andrasina","doi":"10.1080/02656736.2025.2520362","DOIUrl":"https://doi.org/10.1080/02656736.2025.2520362","url":null,"abstract":"<p><strong>Background: </strong>Intraluminal irreversible electroporation (IRE) can be used for recanalizing occluded metal stents. However, optimal IRE parameters for consistent effects across different stent designs remain unclear. The aim of this study was to simulate the process of stent recanalization <i>in silico</i> by employing finite element analysis.</p><p><strong>Methods: </strong>A virtual model of an occluded biliary stent with an experimental 3-electrode IRE catheter was developed. Electric field distribution, temperature changes, and potential ablation volumes were simulated across various parameters: IRE voltage (300 - 1300 V), stent wire width (0.1 - 0.5 mm) and stent mesh size (0.7 - 5.58 mm). Simulations incorporated five representative stent types commonly used in clinical practice. 685 unique simulations were conducted, analyzing 1162 unique values.</p><p><strong>Results: </strong>Higher voltages generally led to larger ablation zones and increased temperatures. Thinner stent wires and larger mesh sizes also increased the extent of ablation zone. While in-stent ablation was largely independent of stent design, out-of-stent ablation was significantly impacted by mesh size and tissue thickness between the stent and irreversible electroporation electrodes. Voltages above 1000 V produced significant thermal effects, with substantial volumes of tissue heated above 50 °C. Specific stent designs exhibited variations in maximum temperature (72.1 - 83.1 °C) and ablation volume (8.7 - 14.7 mm³).</p><p><strong>Conclusion: </strong>Tailored IRE protocols for different stent designs are required due to differences in in- and out-stent ablation volumes. High voltages (>1000 V) induce both thermal and nonthermal ablation mechanisms.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2520362"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous treatment of pulmonary ground-glass opacity nodules with microwave ablation and coaxial puncture biopsy.","authors":"Yibing Li, Mingyuan Hou, Zhenhua Du, Lei Su, Zerui Wang, Fangzhou Jiang, Zhilong Wang, Yining Liang, Taiyang Zuo","doi":"10.1080/02656736.2025.2520879","DOIUrl":"https://doi.org/10.1080/02656736.2025.2520879","url":null,"abstract":"<p><strong>Objective: </strong>To explore the feasibility of microwave ablation combined with coaxial biopsy in the simultaneous treatment of malignant-prone pulmonary ground-glass opacity (GGO) nodules, the advantages and disadvantages of different sequences, and differences in curative efficacy.</p><p><strong>Methods: </strong>We retrospectively analyzed 45 patients (46 lesions) who received microwave ablation combined with coaxial puncture biopsy for pulmonary GGO nodules, with 24 patients (25 lesions) in Group A having biopsies taken after microwave ablation and 21 patients (21 lesions) in Group B having biopsies taken before microwave ablation. By comparing the clinical data, technical success rate, complications, and positive pathological diagnosis rate of the two groups, the advantages and disadvantages of different sequences of puncture biopsy and microwave ablation treatment and their respective efficacies were discussed.</p><p><strong>Results: </strong>The pathological positive diagnosis rates of the two groups were 64.00% and 80.95%, respectively. The pneumothorax rates were 36.00% (9/25) and 33.33% (7/21), respectively, and there were no statistical differences between the two groups (<i>p</i> > 0.05). The incidence rates of intrapulmonary oozing blood in the two groups were 4.00% (3/25) and 28.57% (9/21), respectively, with a statistically significant difference between the two groups (<i>p</i> < 0.05). The rates of complete ablation of the pulmonary nodules at the recent follow-up were 84.00% (21/25) and 71.43% (15/21) in both groups, respectively.</p><p><strong>Conclusion: </strong>Microwave ablation combined with coaxial biopsy is safe, feasible, and effective for treating malignant-prone pulmonary GGO nodules. Sequencing of ablations and biopies has advantages and disadvantages in the diagnosis and treatment of pulmonary GGO.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2520879"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modeling the involution of microwave liver ablation zones.","authors":"William B N Weston, Owen A White, Ruby Callister, Nicos Fotiadis, Joshua Shur, S Nahum Goldberg, Edward W Johnston","doi":"10.1080/02656736.2025.2525422","DOIUrl":"https://doi.org/10.1080/02656736.2025.2525422","url":null,"abstract":"<p><strong>Background: </strong>The post-ablation involution of microwave liver ablation zones (AZs) remains poorly understood. This study develops mathematical models to characterize AZ involution and identifies key predictors influencing its dynamics.</p><p><strong>Materials and methods: </strong>Fifty-four patients (mean age 61 ± 10 years (standard deviation), 33 men) underwent microwave liver ablation (MWA) of 76 liver tumors and follow-up contrast enhanced CT (CECT) imaging in this retrospective single-center cohort study. AZs were segmented on intraprocedural post-ablation portal-venous phase CECT and all available subsequent postprocedural follow-up scans, or until local tumor progression (LTP). Volumetric AZ involution was modeled using non-linear regression methods and correlated with initial tumor and ablation parameters.</p><p><strong>Results: </strong>In total, 366 AZ segmentations were performed over median 304 days CECT-follow-up (range 21-741). Involution was best modeled by mono-exponential decay (SSE = 4.64, RMSE = 0.11). AZs shrank to one-third of baseline volume within a year, with a half-life of 158 days. At 6 weeks, relative volume was 0.81 of baseline (95% prediction interval 0.59-1.04, 95% confidence interval 0.80-0.83). Variables with a significant effect on involution included initial tumor diameter (<i>p</i> = 0.03), initial AZ volume (<i>p</i> < 0.01), and tumor:AZ volume ratio (<i>p</i> = 0.04).</p><p><strong>Conclusions: </strong>Microwave ablation zones rapidly involute and stabilize at approximately one-third of their baseline volume within a year. The involution process is best modeled by mono-exponential decay and influenced by the type of tissue ablated. These findings highlight the potential need for predictive models to adjust for involution for follow-up imaging-based margin assessment to optimize accuracy and ablation outcomes.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2525422"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High intensity focused ultrasound serves as a salvage treatment for uterine arteriovenous fistula when uterine artery embolization fails and pregnancy outcomes: a case report and literature review.","authors":"Shanyu Huang, Mingzhu Ye, Xiaoxiao Xi, Waixing Li, Xiaogang Zhu, Xin Sun","doi":"10.1080/02656736.2025.2519347","DOIUrl":"10.1080/02656736.2025.2519347","url":null,"abstract":"<p><p>Uterine arteriovenous fistula (UAVF) is an abnormal connection formed between the branches of the uterine artery and the venous plexus, accounting for 1%-2% of all reproductive system and abdominal bleeding. In recent years, the incidence has been gradually increasing due to acquired causes such as uterine surgery and pregnancy. The common clinical symptom is painless and irregular vaginal bleeding, which can lead to hemorrhagic shock. There is no standardized and unified treatment for UAVF. At present, uterine artery embolization (UAE) is considered the first-choice treatment for UAVF in clinical practice, but it is prone to treatment failure due to various potential complications. HIFU, as a noninvasive treatment, is currently used in a limited number of cases for the treatment of UAVF, and a few literature reports have shown clinical effects after high-intensity focused ultrasound (HIFU) treatment. This paper reports a case that HIFU was successfully used to treat UAVF after the failure of UAE, and the patient successfully became pregnant, indicating that HIFU can be used as an alternative after the failure of UAE treatment for UAVF, without affecting subsequent pregnancy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519347"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent thrombocytopaenia as an independent risk factor for 28-day mortality and multiorgan failure in exertional heatstroke: a retrospective study of 217 patients.","authors":"Li Zhong, Yan Liu, Conglin Wang, Zheying Liu, Lei Su, Zhifeng Liu, Ming Wu","doi":"10.1080/02656736.2025.2535730","DOIUrl":"https://doi.org/10.1080/02656736.2025.2535730","url":null,"abstract":"<p><strong>Background: </strong>Thrombocytopaenia is a known predictor of poor outcomes in trauma and sepsis patients, its prognostic role in exertional heatstroke (EHS) remains underexplored. This study aimed to evaluate the association between persistent thrombocytopaenia and mortality in critically ill EHS patients.</p><p><strong>Methods: </strong>In this retrospective cohort study, we analyzed data from 217 EHS patients admitted to the intensive care unit (ICU) between November 2009 and October 2023. Demographic, biochemical (baseline, 24 h, and 48 h), and inflammatory marker data were collected. Persistent thrombocytopaenia was defined as a platelet count <100 × 10⁹/L at both 24 h and 48 h postadmission. Multivariate logistic regression identified predictors of 28-day mortality, and Kaplan-Meier survival curves with log-rank tests were used to compare outcomes between groups.</p><p><strong>Results: </strong>Among the 217 patients, 19 (8.8%) patients died within 28 days. Nonsurvivors presented significantly worse liver/kidney function, coagulopathy (DIC incidence: 89.5% vs. 26.8%, <i>p</i> < 0.001), and AKI incidence (100% vs. 38.4%, <i>p</i> < 0.01). The platelet counts in nonsurvivors were markedly lower than those in survivors at admission (71 vs. 166 × 10⁹/L), 24 h (49 vs. 134 × 10⁹/L), and 48 h (56 vs. 131 × 10⁹/L) (all <i>p</i> < 0.001). Persistent thrombocytopaenia (63 patients, 29.0%) independently predicted mortality (adjusted OR = 17.44, 95% CI: 4.76-63.86; <i>p</i> < 0.001) and was correlated with higher DIC (84.1% vs. 11.0%, <i>p</i> < 0.001) and AKI (63.5% vs. 35.7%, <i>p</i> < 0.001) rates. Survival analysis confirmed significantly increased 28-day mortality in thrombocytopaenia patients (25.4% vs. 1.9%, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Persistent thrombocytopaenia within 48 h of ICU admission is a robust predictor of mortality and multiorgan dysfunction in patients with EHS.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2535730"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blocking Tim-3 enhances CD8⁺ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation.","authors":"Na Wu, Xinru Pei, Weiguo Cai, Xiaodie Ye, Wei Lu","doi":"10.1080/02656736.2025.2516502","DOIUrl":"https://doi.org/10.1080/02656736.2025.2516502","url":null,"abstract":"<p><strong>Background: </strong>Incomplete radiofrequency ablation (iRFA) for hepatocellular carcinoma (HCC) during radiofrequency ablation (RFA) may result in rapid progression of residual tumors and resistance to anti-PD-1 therapy. Research has demonstrated elevated T-cell immunoglobulin and mucin domain 3 (Tim-3) expression in CD8⁺ T cells in the peripheral blood of patients with HCC after RFA, leading to a diminished anti-tumor immune response. Therefore, this study examined the effectiveness of anti-Tim-3 therapy in treating residual tumors after iRFA and explored the underlying mechanisms.</p><p><strong>Methods: </strong>To examine the expression of Tim-3 in the residual tumors after iRFA for HCC in mice. Treat residual tumors with anti-αTim-3 and evaluate its efficacy. Transcriptomic sequencing was conducted on the residual tumors to explore the underlying mechanisms. Meanwhile, residual tumors were treated with a combination of anti-αTim-3 and anti-αPD-1 to evaluate efficacy.</p><p><strong>Results: </strong>This study demonstrated elevated Tim-3 expression in CD8⁺ T cells within residual tumors after iRFA. CD8⁺ T cells exhibit attenuated anti-tumor immune responses associated with accelerated tumor progression. Treatment with anti-αTim-3 impeded the advancement of residual tumors by enhancing CD8⁺ T cell infiltration and stimulating their anti-tumor activities. Furthermore, anti-αTim-3 therapy upregulated PD-1 expression in residual tumors. Combination therapy involving anti-αTim-3 and anti-αPD-1 elicited a robust anti-tumor immune response.</p><p><strong>Conclusions: </strong>Tim-3 expression is elevated in CD8⁺ T cells within residual tumors after iRFA, which contributed to their accelerated advancement. Anti-αTim-3 slows tumor progression by boosting CD8⁺ T cell anti-tumor activity and enhancing response to anti-αPD-1 treatment.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2516502"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}